JP7136763B2 - フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 - Google Patents

フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 Download PDF

Info

Publication number
JP7136763B2
JP7136763B2 JP2019500212A JP2019500212A JP7136763B2 JP 7136763 B2 JP7136763 B2 JP 7136763B2 JP 2019500212 A JP2019500212 A JP 2019500212A JP 2019500212 A JP2019500212 A JP 2019500212A JP 7136763 B2 JP7136763 B2 JP 7136763B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
total weight
less
sodium phenylbutyrate
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509345A5 (enExample
JP2019509345A (ja
Inventor
イー． アッペル，レア
アール． ショッキー，ジョシュア
シェリング，ディー．クリストファー
Original Assignee
エイサー セラピューティクス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイサー セラピューティクス インコーポレーテッド filed Critical エイサー セラピューティクス インコーポレーテッド
Publication of JP2019509345A publication Critical patent/JP2019509345A/ja
Publication of JP2019509345A5 publication Critical patent/JP2019509345A5/ja
Priority to JP2022076939A priority Critical patent/JP2022106927A/ja
Application granted granted Critical
Publication of JP7136763B2 publication Critical patent/JP7136763B2/ja
Priority to JP2024055290A priority patent/JP2024081748A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2019500212A 2016-03-15 2016-10-17 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 Active JP7136763B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022076939A JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2024055290A JP2024081748A (ja) 2016-03-15 2024-03-29 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
US62/308,614 2016-03-15
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076939A Division JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2019509345A JP2019509345A (ja) 2019-04-04
JP2019509345A5 JP2019509345A5 (enExample) 2019-11-28
JP7136763B2 true JP7136763B2 (ja) 2022-09-13

Family

ID=59847918

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019500212A Active JP7136763B2 (ja) 2016-03-15 2016-10-17 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2022076939A Withdrawn JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2024055290A Pending JP2024081748A (ja) 2016-03-15 2024-03-29 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022076939A Withdrawn JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2024055290A Pending JP2024081748A (ja) 2016-03-15 2024-03-29 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Country Status (23)

Country Link
US (5) US20170266115A1 (enExample)
EP (2) EP3429559B1 (enExample)
JP (3) JP7136763B2 (enExample)
KR (3) KR102690703B1 (enExample)
AU (1) AU2016398029B2 (enExample)
BR (1) BR112018068665B1 (enExample)
CA (1) CA3017573A1 (enExample)
CY (1) CY1125450T1 (enExample)
DK (1) DK3429559T3 (enExample)
ES (1) ES2922749T3 (enExample)
HR (1) HRP20220856T1 (enExample)
HU (1) HUE059630T2 (enExample)
IL (3) IL296490B1 (enExample)
LT (1) LT3429559T (enExample)
MX (2) MX391305B (enExample)
PL (1) PL3429559T3 (enExample)
PT (1) PT3429559T (enExample)
RS (1) RS63383B1 (enExample)
SA (1) SA518400020B1 (enExample)
SG (1) SG11201807979SA (enExample)
SI (1) SI3429559T1 (enExample)
SM (1) SMT202200386T1 (enExample)
WO (1) WO2017160345A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296490B1 (en) 2016-03-15 2025-09-01 Acer Therapeutics Inc Tasty compositions containing sodium phenylbutyrate and their uses
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005060310A (ja) 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
JP2005508901A (ja) 2001-09-10 2005-04-07 ルナメト アクチェンゲゼルシャフト 活性成分を徐放する剤形
JP2007525413A (ja) 2003-01-24 2007-09-06 アール．ピー． シェーラー テクノロジーズ インコーポレイテッド 味をマスクした有効物質の結晶または顆粒の分散体、分散体を詰めた咀嚼ソフトカプセル、およびその調製方法
JP2008280351A (ja) 2001-07-20 2008-11-20 Novartis Ag テルビナフィンを含有する医薬組成物およびその使用
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
JP2014521713A (ja) 2011-08-12 2014-08-28 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 味をマスキングした医薬組成物
JP2015533164A (ja) 2012-10-15 2015-11-19 ニュー ジャージー インスティチュート オブ テクノロジー 味マスクされた活性医薬粉末組成物およびその製造方法
JP2016006025A (ja) 2014-05-26 2016-01-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2561855A1 (en) * 2004-04-12 2005-10-20 Pfizer Products Inc. Taste-masked drugs in rupturing multiparticulates
CA2687192C (en) * 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
JP4706785B2 (ja) * 2008-09-30 2011-06-22 アステラス製薬株式会社 経口投与用粒子状医薬組成物
PT2456304E (pt) 2009-07-24 2015-10-12 Baylor College Medicine Métodos de modulação de ácidos de cadeia ramificada e utilização dos mesmos
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
WO2012077038A1 (en) 2010-12-06 2012-06-14 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US8897280B2 (en) * 2011-03-29 2014-11-25 Qualcomm Incorporated System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols
WO2012156997A2 (en) * 2011-05-16 2012-11-22 Sun Pharma Advanced Research Company Ltd Multi-particulate pharmaceutical composition
AU2012265842A1 (en) 2011-06-07 2014-01-23 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
RU2014100048A (ru) * 2011-06-22 2015-07-27 Гмп-Орфан Соль 4-фенилбитурата, предназначенная для лечения болезни моторных нейронов или метаболического заболевания при ректальном введении
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
CN105560203A (zh) 2013-01-28 2016-05-11 万平 定位速释生物粘附剂及其制备方法和应用
IL296490B1 (en) 2016-03-15 2025-09-01 Acer Therapeutics Inc Tasty compositions containing sodium phenylbutyrate and their uses

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008280351A (ja) 2001-07-20 2008-11-20 Novartis Ag テルビナフィンを含有する医薬組成物およびその使用
JP2005508901A (ja) 2001-09-10 2005-04-07 ルナメト アクチェンゲゼルシャフト 活性成分を徐放する剤形
JP2007525413A (ja) 2003-01-24 2007-09-06 アール．ピー． シェーラー テクノロジーズ インコーポレイテッド 味をマスクした有効物質の結晶または顆粒の分散体、分散体を詰めた咀嚼ソフトカプセル、およびその調製方法
JP2005060310A (ja) 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
JP2014521713A (ja) 2011-08-12 2014-08-28 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 味をマスキングした医薬組成物
JP2015533164A (ja) 2012-10-15 2015-11-19 ニュー ジャージー インスティチュート オブ テクノロジー 味マスクされた活性医薬粉末組成物およびその製造方法
JP2016006025A (ja) 2014-05-26 2016-01-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法

Also Published As

Publication number Publication date
EP3429559A4 (en) 2019-11-06
RS63383B1 (sr) 2022-08-31
AU2016398029A1 (en) 2018-10-11
US20170266115A1 (en) 2017-09-21
US20230133629A1 (en) 2023-05-04
HUE059630T2 (hu) 2022-11-28
ES2922749T3 (es) 2022-09-20
US11154521B2 (en) 2021-10-26
BR112018068665A2 (pt) 2019-02-05
SG11201807979SA (en) 2018-10-30
MX2018011229A (es) 2019-05-30
KR20240119184A (ko) 2024-08-06
US11202767B2 (en) 2021-12-21
JP2022106927A (ja) 2022-07-20
IL261777B (en) 2022-10-01
EP3429559A1 (en) 2019-01-23
CA3017573A1 (en) 2017-09-21
SMT202200386T1 (it) 2022-11-18
IL261777B2 (en) 2023-02-01
KR20190008840A (ko) 2019-01-25
US11433041B2 (en) 2022-09-06
WO2017160345A8 (en) 2018-02-22
SI3429559T1 (sl) 2022-11-30
WO2017160345A1 (en) 2017-09-21
EP4104822A1 (en) 2022-12-21
PL3429559T3 (pl) 2022-11-07
CY1125450T1 (el) 2025-05-09
PT3429559T (pt) 2022-07-20
US20210186908A1 (en) 2021-06-24
US20210220304A1 (en) 2021-07-22
KR20250150154A (ko) 2025-10-17
KR102865751B1 (ko) 2025-09-29
IL322955A (en) 2025-10-01
IL261777A (en) 2018-10-31
MX391305B (es) 2025-03-21
KR102690703B1 (ko) 2024-08-02
JP2024081748A (ja) 2024-06-18
IL296490A (en) 2022-11-01
US20200261385A1 (en) 2020-08-20
HRP20220856T1 (hr) 2022-10-14
IL296490B1 (en) 2025-09-01
EP3429559B1 (en) 2022-04-13
DK3429559T3 (da) 2022-07-11
SA518400020B1 (ar) 2022-12-21
BR112018068665B1 (pt) 2023-12-26
JP2019509345A (ja) 2019-04-04
LT3429559T (lt) 2022-08-10
AU2016398029B2 (en) 2023-03-02
MX2022003969A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
JP7136763B2 (ja) フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
EP1940361B1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
US10881614B2 (en) Nicotinamide compositions and the therapeutic use thereof
JPH07509702A (ja) ペレット薬剤組成物
CN105682648A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
AU5432401A (en) Oral solid pharmaceutical formulations with ph-dependent multiphasic release
BRPI0621633A2 (pt) composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
EP3638211B1 (en) Delayed sustained release pharmaceutical compositions
EP3184101A1 (en) Levodopa and carbidopa modified release composition
JP2003512311A (ja) Ｃｎｓ介在性障害を治療するための持続放出製剤
EP4433034A1 (en) Controlled release formulations of flavoxate and process for preparation thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210617

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220901

R150 Certificate of patent or registration of utility model

Ref document number: 7136763

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250